Bill Taranto

And the data component around that, you know, as we now then get access to more data on a global basis, you know, combining that in the use of AI on the data side with AI on the clinical side is going to help dramatically, which we're seeing in AI in drug development side, right?

You know, the use of broad data sets in discovery and development is what's going to change the industry.

So it's both those kind of areas will work together, I think, to provide the value that AI is going to bring.

Again, it's in its infancy, though.

Well, you know, we'll see.

But we're big believers in it.

We're investing in it.

Not really, because it's not... Those are all...

corporate things that Merck will figure out what they want to do, but they don't really affect the areas that we focus on in those sort of four buckets going forward.

Um, you know, I think more around the things that are important to us as investors, how does the industry, um, think about approving and adopting technologies from an FDA perspective faster?

Um,

You know, that would be a great thing, loosening some of the regulations on pharma.

You know, for example, we have a company called WellDoc, which is sort of in the Livongo realm around diabetes management.

And it's just it's a really fascinating app that helps you manage your diabetes with tons of clinical data to support that it works.

We actually can't give that out to the patient.

Everybody knows that if you're on a diabetes drug, having this app is the right thing to do.

Like there's nobody that would question it.

But due to regulatory rules around anti-kickback statutes and sunshine laws, we can't give that app out for free, even though one would say that is the best interest of the patient.

So how do we loosen some of the regulatory environment around that?

How patients use some of the tools that are out there, not just what we're investing, but what everybody's investing in and give them better access.